The impact of IL-10 gene polymorphism 1082A/G (rs1800896) on increased IL-10 secretion in patients with chronic kidney disease in the Kurdistan Region of Iraq // Impacto del polimorfismo 1082A/G (rs1800896) del gen de IL-10 sobre la secreción de IL-10 en pacientes con enfermedad renal crónica en la región Kurdistán de Irak

Sarhang H. Azeez, Suhaila N. Darogha



Studies have indicated that interleukin-10 gene polymorphism at 1082A/G is associated with chronic kidney disease (CKD). The aim of this study was to determine Il-10 gene polymorphism in CKD patients and identify the risk factors and prevalence of the disease among Kurdish patients. It was also aimed at finding out the serum levels of IL-10 in different genotypes, AA, GA and GG. The study included 108 patients with CKD: 54 on hemodialysis (HD) and 54 renal-transplanted (RT) and 54 healthy subjects. The mean age for HD, RT and healthy subjects was respectively 46.1, 36.8 and 40.2. Half of the HD patients and healthy subjects (50%) were male and half were female, while 55.6% of the RT patients were male and 44.4% female. According to the allele frequency of both G and A, there was no significant difference between both groups of patients and the healthy subjects (P=0.42). The AG genotype was independently associated with increased risk of CKD undergoing HD and RT, while the GG genotype showed an increased risk for renal failure. The levels of serum IL-10 concentrations increased significantly in both groups of patients compared to the healthy subjects. Regarding the genotypes, the genotype AA had the highest concentration among the patients, while a high level was found in genotype GA in the healthy subjects. The lowest level of this cytokine was found in both genotypes GG and AA in the healthy subjects. The findings of the present study revealed that IL-10 gene polymorphism at 1082 A/G (rs1800896) and increased concentration of serum IL-10 were associated with increasing chronic kidney disease in the Iraqi Kurdish population.


Varios estudios han indicado que el polimorfismo 1082A/G (rs1800896) del gen de IL-10 está asociado con la enfermedad renal crónica (ERC). El propósito de este estudio fue determinar el polimorfismo del gen de la IL-10 en pacientes con ERC e identificar los factores de riesgo y prevalencia de la enfermedad entre pacientes Kurdos. También se determinaron las concentraciones séricas de IL-10 en los diferentes genotipos AA, GA y GG presentes. El estudio incluyó 108 pacientes con ERC: 54 en hemodiálisis (HD) y 54 con trasplante renal (TR) y en 54 sujetos sanos. Las edades promedio para los HD, TR y sujetos sanos fueron 46,1, 36,8 y 40,2 años, respectivamente. La mitad de los pacientes en HD y de los sujetos sanos eran hombres y la otra mitad eran mujeres, mientras que el 55,6% de los pacientes con TR eran hombres y 44,4 % eran mujeres. Considerando la frecuencia de los alelos G y A, no hubo diferencias estadísticamente significativas entre ambos grupos de pacientes y los sujetos sanos (p= 0,42). El genotipo AG se encontró independientemente asociado con un riesgo aumentado de pacientes con ERC bajo HD y TR, mientras que el genotipo GG mostró un riesgo mayor de falla renal. Las concentraciones séricas de IL-10 se encontraron aumentadas significativamente en ambos grupos de pacientes, comparadas con las de los sujetos sanos. En consideración a los genotipos, el genotipo AA tenía las más altas concentraciones entre los pacientes, mientras que se encontró un mayor nivel en el genotipo GA en los sujetos sanos. Las concentraciones más bajas de esta citocina se encontraron en los genotipos GG y AA de los sujetos sanos. Los hallazgos del presente estudio revelaron que el polimorfismo 1082A/G (rs1800896) del gen de la IL-10 y las concentraciones séricas aumentadas de IL-10 estaban asociadas con aumentos de la enfermedad renal crónica en la población Kurda de Iraq.

Palabras clave

chronic kidney disease; polymorphism; interleukin-10; enfermedad renal crónica; polimorfismo; interleucina-10

Texto completo:



Pedro T, Sara A, Combs, and Isaac T.Peritoneal dialysis: update on patient survival. Clin Nephrol 2015; 83: 1-10.

Rios D, Pinheiro M, de Oliveira Junior W, Braga K, Carvalho A, Martins-Filho O, Simões E, Silva AC, Dusse LMS.Cytokine signature in end-stage renal disease patients on emodialysis. Dis Markers 2017; 9678391.

Zahed NS and Chehrazi S.The evaluation of the relationship between serum levels of interleukin-6 and interleukin-10 and metabolic acidosis in hemodialysis patients. Saudi J Kidney Dis Transpl 2017; 28(1):23-29.

Daichou Y, Kurashige S, Hashimoto S, Suzuki S. Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron 1999; 83: 237-245.

Ando M, Shibuya A, Yasuda M, Azuma N, Tsuchiya K, Akiba T, Nitta K.Impairment of innate cellular response to in vitro stimuli in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2005; 20: 2497-2503.

Girndt M, Ulrich C, Kaul H, Sester U, Sester M, Kohler H.Uremia-associated immune defect: The IL-10- CRP axis. Kidney Int Suppl 2003; 84: 76-79.

Menon V, Greene T, Wang X, Pereira A, Marcovina S, Beck G, Kusek JW, Collins AJ, Levey AS, Sarnak MJ.C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772. 8. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B.Serum albumin, Creactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148.

Stenvinkel P.Inflammation in end-stage renal disease: the hidden enemy. Nephrology Carlton 2006a; 11: 36-41.

Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis cytokines (IFN-γ, TNF-α, IL-10 and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003; 14: 1776-1784.

Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition- inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773.

Stenvinkel P.New insights on inflammation in CKD genetic and non-genetic factors. Nephrol Ther 2006; 2: 111-119.

De Francisco A, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2009; 2 (1):18-26.

Luo X, Miller S, Shea L.Immune tolerance for autoimmune disease and cell transplantation. Ann Rev Biomed Eng 2016; 18: 181–205.

Girndt M.Humoral immune responses in uremia and the role of IL-10. Blood Purif 2002; 20: 485-488.

Seyrek N, Karayaylali I, Balal M, Paydas S, Aikimbaev K, Cetiner S, Seydaoglu G. Is there any relationshipbetween serum levels of interleukin-10 and atherosclerosis in hemodialysis patients. Scand J Urol Nephrol 2005; 39: 405-409.

Girndt M, Heine GH, Kohler H, Dial Gene Consortium. Gene polymorphism association studies in dialysis: Anemia and host immunity. Semin Dial 2006; 19: 227-31.

Litjens N, Huisman M, van den Dorpel M, Betjes M.Impaired immune responsesand antigen-specific memory CD4+ T cells in haemodialysis patients. J Am Soc Nephrol 2008; 19: 1483-1490.

Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P.Polymorphic haplotypes of the interleukin-10 5_ flanking region determine variable interleukin- 10 transcription and are associated with particular phenotypes ofjuvenile rheumatoid arthritis. Arth Rheum 1999; 42 (6):1101– 1108.

Mäurer M, Kruse N, Giess R, Toyka K, Riekmann P.Genetic variationat position-1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis. J Neuroimmunol 2000; 104(1):98-100.

Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M, Metanat M, Khosravi S, Farrokh P. Association between IL-10 gene promoter polymorphisms (-592 A/C, -819 T/C, -1082 A/G) and susceptibility to HBV infection in an Iranian population. Hepatitis Monthly 2016; 16(2): e32427.

Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T, Kohler H.Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949-955.

Wilson AG, DE Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor-alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177:557–560.

Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, Tao L, Sun H, Kellems RE, Blackburn MR, Xia Y. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 2012; 59:136-44.

Brunet P, Capo C, Dellacasagrande J, Thirion X, Mege JL, Berland Y.IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. Nephrol Dial Transplant 1998; 13:1745-51.

Stenvinkel P, Ketteler M, Johnson R, Lindholm B, Pecoits-Filho R, Riella M. IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia: The good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233.

Loppnow H, Werdan K, Buerke M.Vascular cells contribute to atherosclerosis by cyto- Impact of IL-10 gene polymorphism 1082A/G (rs1800896) on increased IL-10 secretion 37 Vol. 60(1): 29 - 37, 2019 kine- and innate-immunity-related inflammatory mechanisms. Innate Immun 2008; 14: 63-87.

Han X, Kitamoto S, Lian Q, Boisvert WA. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J Biol Chem 2009; 284: 32950-32958.

Liu Z, Guo J, Wang Y, Li K, Wei Y, Sun Q, XuQ, XuC, Ya nX, TangB. Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinson’s disease with cognitive impairment in a Chinese population. Scientific Reports 2016; 6:19021.

Ori Y, Bergman M, Bessler H, Zingerman B, Levy-Drummer R, Gafter U, Salman H. Cytokine secretion and markers of inflammation in relation to acidosis among chronic hemodialysis patients. Blood Purif 2013; 35:181-6.

Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH.Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54:236-44.

Castillo-Rodríguez E, Pizarro-Sánchez S, Sanz AB, Ramos AM, Sanchez-Niño MD, Martin-Cleary C, Fernandez-Fernandez B, Ortiz A. Inflammatory cytokines as uremic toxins: “ni son todos los que están, ni están todos los que son”. Toxins 2017: 9(4)114.

Sinuani I, Beberashvili I, Averbukh Z and Sandbank J.Role of IL-10 in the progression of kidney disease. W J Trans 2013; 3(4): 91–98.

Iyer S, and Cheng G.Role of Interleukin 10 Transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol 2012; 32(1): 23–63.

Guo J, He Y, Chen F, Jiang M, Gao S, Su Y.The A to G polymorphism at -1082 of the interleukin-10 gene is rare in the Han Chinese population. Mol Med Rep 2012; 6: 894-896.

Vaidyanathapuram S, Balakrishnan, Daqing G, Madhumathi R, Bertrand L, Jaber H. Cytokine gene polymorphisms in hemodialysis patients: Association with comorbidity, functionality, and serum albumin. Kidney Int 2004; 65: 1449–1460

Universidad del Zulia / Venezuela / Investigación Clínica / / p-ISSN: 0535-5133 / e-ISSN: 2477-9393


Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 3.0 Unported.